Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050549 | 0.87 | CYP1A2 (0.58) | ALDH1A1HSD17B10TSHRMAPK1ATM | |
| SCHEMBL30476092 | 0.87 | CYP1A2 (0.58) | ALDH1A1HSD17B10TSHRMAPK1ATM | |
| SCHEMBL29363189 | 0.85 | ALDH1A1 (0.62) | ALDH1A1HSD17B10TSHRMAPK1ATM | |
| SCHEMBL70219 | 0.85 | ALDH1A1 (0.62) | ALDH1A1HSD17B10TSHRMAPK1ATM | |
| SCHEMBL18347018 | 0.85 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TSHRMAPK1ATM | |
| SCHEMBL30704460 | 0.84 | ALDH1A1 (0.60) | ALDH1A1HSD17B10TSHRMAPK1ATM | |
| SCHEMBL16051127 | 0.84 | ALDH1A1 (0.60) | ALDH1A1HSD17B10TSHRMAPK1ATM | |
| SCHEMBL7126508 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HSD17B10TSHRL3MBTL1MCL1 | |
| SCHEMBL9115296 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HSD17B10TSHRMAPK1ATM | |
| Catechol SCHEMBL8935190 | 0.80 | ALDH1A1 (0.59) | ALDH1A1HSD17B10TSHRMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10072405-A | — | — | None | — | — | JP | disclosed |
| JP-9169786-A | — | — | None | — | — | JP | disclosed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20190280218-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2019-09-12 | — | — | US | disclosed |
| US-20190280218-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2019-09-12 | — | — | US | disclosed |
| EP-2841422-B1 | METHODS FOR THE SYNTHESIS OF ETHYLFUMARATES AND THEIR USE AS INTERMEDIATES | MANNKIND CORP (US) | 2019-08-28 | — | — | EP | disclosed |
| US-10374170-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2019-08-06 | — | — | US | disclosed |
| US-10374170-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2019-08-06 | — | — | US | disclosed |
| EP-3077382-A2 | SUBSTITUTED OXEPINES | Merck Patent GmbH (DE) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015082046-A2 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015082046-A2 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2015-06-11 | — | — | WO | disclosed |
| EP-1768943-B1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | IND TECH RES INST (CN) | 2008-12-17 | — | — | EP | disclosed |
| US-6916940-B2 | Method for producing cyclic carboxylic orthoester fluorides and corresponding compounds | MERCK PATENT GMBH (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20040054196-A1 | Method for producing cyclic carboxylic orthoester fluorides and corresponding compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2004-03-18 | — | — | US | disclosed |
| EP-1326855-A1 | METHOD FOR PRODUCING CYCLIC CARBOXYLIC ORTHOESTER FLUORIDES AND CORRESPONDING COMPOUNDS | MERCK PATENT GmbH (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002034740-A1 | METHOD FOR PRODUCING CYCLIC CARBOXYLIC ORTHOESTER FLUORIDES AND CORRESPONDING COMPOUNDS | MERCK PATENT GMBH (DE) | 2002-05-02 | — | — | WO | disclosed |
| JP-H1072405-A | OPTICALLY ACTIVE ALPHA, BETA-UNSATURATED ESTER AND OPTICALLY ACTIVE ESTER COMPOUND DERIVED THEREFROM | NAGASE & CO LTD | 1998-03-17 | — | — | JP | disclosed |
| JP-H09169786-A | TERTIARY PHOSPHINE COMPOUND AND ITS USE | FUJISAWA PHARMACEUT CO LTD | 1997-06-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11917913-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | ALDH1A1 1740/4885HSD17B10 4302/4885TSHR 4405/4885 |
| US-20040054196-A1 | Method for producing cyclic carboxylic orthoester fluorides and corresponding compounds | OXSR1, CBR3, PFAS | ALDH1A1 1093/4885HSD17B10 975/4885TSHR 116/4885 |
| US-10374170-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | ALDH1A1 1740/4885HSD17B10 4302/4885TSHR 4405/4885 |
| US-20190280218-A1 | SUBSTITUTED OXEPINES | OXGR1, OXTR, OCIAD2 | ALDH1A1 1740/4885HSD17B10 4302/4885TSHR 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.